We observe decreased CRISP3 levels in bone marrow specimens from MM patients compared to the NCBD group (p < 0.05), as well as downregulated expression in the MM group with poor prognosis (p < 0.05), which further characterizes it as a potential tumor suppressor. Here, CRISP3 is linked to Miyoshi myopathy.